James I. Geller, MD
Appointment
Assistant Professor of Clinical Pediatrics
Email
james.geller@cchmc.org
Phone
513-636-4266
Fax
513-636-3549
Bio
James I. Geller, MD completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of Assistant Professor of Clinical Pediatrics.
Dr. Geller's professional interests include the clinical care of children with cancer, Phase I and Phase II clinical investigation targeted at the development of new therapeutic approaches for children with refractory cancer, and correlative assessment of cancer biology as adjuncts to prospective clinical trials.
Dr. Geller completed three years of intensive laboratory investigation focused on elucidating ways to rationally and effectively translate the use of biological response modifiers, active in modulating cell death (apoptosis) signaling pathways, in combination with conventional chemotherapeutics. While currently directly involved with several clinical and biological research investigations resulting from such laboratory experience, Dr. Geller is currently working on three new separate clinical research trials for which he will guide the investigation as the principal investigator. Two of the trials focus on the employment of immunotherapy / biological response modifiers in combination with chemotherapy for refractory solid tumors, and another focuses on a new therapeutic approach for children with refractory Acute Myeloid Leukemia.
Dr. Geller has also been prolific in publishing cancer biology insights that serve as pre-clinical justification for future clinical trials, as well as clinical insights that aid in tailoring the approach to the clinical care of children with cancer. He is an active member of the Department of Hematology / Oncology, as well as an active member of the Children's Oncology Group, where he currently serves on the Renal Tumor Committee.
Credentials
MD: Sackler School of Medicine, 1997.
Residency: New York Medical College, 2000.
Fellowship: St Jude Children's Research Hospital, 2004.
Certification: Pediatrics, 2000; Pediatric Hematology / Oncology, 2005.
Awards and Honors
National Research Service Award (NIH Training Grant, T32-CA70089), 7/02-7/04
Research
- Developmental therapeutics
- Cytokine / Immunotherapy
- AML
- Neuro-Oncology
- Renal Cell Carcinoma
Research Grants and Contracts
ROI CA108929-01 - Sub-contractee, Developmental Therapy for Metastatic Colorectal Cancer.
Dr. Geller has been subcontracted for various protocol oversight, data assimilation and publication responsibilities (2005-2008).
IRB approved or CTEP approved investigations:
Role: Co-Principal Investigator
Title: Molecular Correlates of FUra, IFN-g), and Fas Signaling Pathways with Chemotherapeutic Response in Colorectal Carcinoma: a supplemental protocol for the Phase I / II study of Interferon-gamma (IFN-g) added to Bolus + Infusional 5-Fluorouracil (FUra) and Leucovorin (LV) + / - Bevacizumab in Metastatic Colorectal Carcinoma (GFL / GFLA Trial).
Role: Co-Investigator
Title: Phase I / II study of Interferon-gamma (IFN-g) added to Bolus + Infusional 5-Fluorouracil (FUra) and Leucovorin (LV) + / - Bevacizumab in Metastatic Colorectal Carcinoma (GFL + / - BV Trial) (protocol open to accrual) (PI: Lee Schwartzberg, MD, West Clinic, Memphis, TN.)
Role: Co-Investigator
Title: Therapeutic and Biological Study of High-Risk 'Rare' Renal Tumors. Principal Investigator for the characterization and biological study of Renal Cell Carcinoma- a COG study-AREN0321 (PI- Jeff Dome, MD).
Role: Co-Investigator
Title: [F-18] Fluoro-DOPA PET Imaging of Brain Tumors in Children – a Cincinnati Children's Hospital Medical Center internal trial.
Publications, Most Recent
Connect to James Geller's publications on PubMed
Geller J and Dome J. Local Lymph Node Involvement Does Not Predict Poor Outcome in Pediatric Renal Cell Carcinoma, Cancer, 101:1575-1583, October 1, 2004.
Geller J, Szekely Szucs K and Houghton, J. P21 is a critical mediator of cytotoxicity from ZD9331-induced thymineless stress in colorectal carcinomas, Can Res, 64:6296-6303, September 1, 2004.
Geller J and Santana VM. Tumor Rupture and Mitotic Index in Pediatric Sex Cord-Stromal Tumors, J Clin Onc, 2032-2033, May 15 2004.
Geller J, Petak I, Szekely Szucs K, Nagy K, Tillman DM, Houghton JA. Interferon-g-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the IAP survivin, Clin Can Res: 6504-6515, December 15, 2003.
Geller J, Kronn, D, Jayabose, S, Sandoval, C. Hereditary Folate Malabsorption, Family Report and Review of the Literature, Medicine: 81: 51-68, 2002.
Recent Presentations
Geller J, Concept Proposal: Clinical and Biological study of Renal Cell Carcinoma in Pediatric Patients. Children's Oncology Group Fall Meeting, St. Louis, MO, 2002.
Professional Organization Memberships
- American Society of Pediatric Hematology/Oncology
- American Society of Clinical Oncology
- American Society of Hematology
- American Association for Cancer Research
- American Academy of Pediatrics
Abstracts
Geller J, Szekely-Szucs K, Doyle B, Houghton JA: P21 is a critical mediator of cytotoxicity of thymidilyate synthase inhibitors (TSI) in colorectal carcinoma cells (cc). PAACR 44:4869, March, 2004. (Poster)
Geller J, Tillman M, VanCleve T, Houghton JA: Flavopiridol and 5-Fluorouracil display DNA and RNA-damage dependent and sequence-dependent synergistic cytotoxicity in colorectal carcinoma cell lines (cc). PAACR 45:2963, March, 2004. (Poster)
Geller J, Petak I, Nagy K, Tillman DM, Szekely Szucs K, Houghton JA: Interferon-g (IFN-g) sensitizes colon carcinomas (cc) to the selective thymidylate synthase (TS) inhibitor, ZD9331, at additional sites downstream of Fas.PAACR 44:1056, March, 2003. (Poster)
Special Interests
Pediatric oncology
Editorial Positions
Ad hoc journal referee for the following journals:
- Cancer Research
- Journal of Molecular Medicine
- Molecular Pharmacology
- Pediatric Blood & Cancer
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
